These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 18657507)

  • 1. Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2's inhibition of apoptotic calcium signals.
    Rong YP; Aromolaran AS; Bultynck G; Zhong F; Li X; McColl K; Matsuyama S; Herlitze S; Roderick HL; Bootman MD; Mignery GA; Parys JB; De Smedt H; Distelhorst CW
    Mol Cell; 2008 Jul; 31(2):255-65. PubMed ID: 18657507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Bcl-2-IP
    Distelhorst CW
    Biochim Biophys Acta Mol Cell Res; 2018 Nov; 1865(11 Pt B):1795-1804. PubMed ID: 30053503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bcl-2 and IP
    Ivanova H; Wagner LE; Tanimura A; Vandermarliere E; Luyten T; Welkenhuyzen K; Alzayady KJ; Wang L; Hamada K; Mikoshiba K; De Smedt H; Martens L; Yule DI; Parys JB; Bultynck G
    Cell Mol Life Sci; 2019 Oct; 76(19):3843-3859. PubMed ID: 30989245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptor.
    Rong YP; Bultynck G; Aromolaran AS; Zhong F; Parys JB; De Smedt H; Mignery GA; Roderick HL; Bootman MD; Distelhorst CW
    Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14397-402. PubMed ID: 19706527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The trans-membrane domain of Bcl-2α, but not its hydrophobic cleft, is a critical determinant for efficient IP3 receptor inhibition.
    Ivanova H; Ritaine A; Wagner L; Luyten T; Shapovalov G; Welkenhuyzen K; Seitaj B; Monaco G; De Smedt H; Prevarskaya N; Yule DI; Parys JB; Bultynck G
    Oncotarget; 2016 Aug; 7(34):55704-55720. PubMed ID: 27494888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The selective BH4-domain biology of Bcl-2-family members: IP3Rs and beyond.
    Monaco G; Vervliet T; Akl H; Bultynck G
    Cell Mol Life Sci; 2013 Apr; 70(7):1171-83. PubMed ID: 22955373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Bcl-2 based on the interaction of its BH4 domain with the inositol 1,4,5-trisphosphate receptor.
    Rong YP; Barr P; Yee VC; Distelhorst CW
    Biochim Biophys Acta; 2009 Jun; 1793(6):971-8. PubMed ID: 19056433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Constitutive IP
    Bittremieux M; La Rovere RM; Akl H; Martines C; Welkenhuyzen K; Dubron K; Baes M; Janssens A; Vandenberghe P; Laurenti L; Rietdorf K; Morciano G; Pinton P; Mikoshiba K; Bootman MD; Efremov DG; De Smedt H; Parys JB; Bultynck G
    Cell Death Differ; 2019 Mar; 26(3):531-547. PubMed ID: 29899382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum.
    Akl H; Vervloessem T; Kiviluoto S; Bittremieux M; Parys JB; De Smedt H; Bultynck G
    Biochim Biophys Acta; 2014 Oct; 1843(10):2240-52. PubMed ID: 24768714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tracing the evolutionary history of Ca
    Rosa N; Shabardina V; Ivanova H; Sebé-Pedrós A; Yule DI; Bultynck G
    Biochim Biophys Acta Mol Cell Res; 2021 Nov; 1868(12):119121. PubMed ID: 34400171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IP3R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP3R-derived peptide targeting the BH4 domain of Bcl-2.
    Akl H; Monaco G; La Rovere R; Welkenhuyzen K; Kiviluoto S; Vervliet T; Molgó J; Distelhorst CW; Missiaen L; Mikoshiba K; Parys JB; De Smedt H; Bultynck G
    Cell Death Dis; 2013 May; 4(5):e632. PubMed ID: 23681227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double point mutation at residues Ile14 and Val15 of Bcl-2 uncovers a role for the BH4 domain in both protein stability and function.
    Monaco G; La Rovere R; Karamanou S; Welkenhuyzen K; Ivanova H; Vandermarliere E; Di Martile M; Del Bufalo D; De Smedt H; Parys JB; Economou A; Bultynck G
    FEBS J; 2018 Jan; 285(1):127-145. PubMed ID: 29131545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcl-2 and FKBP12 bind to IP3 and ryanodine receptors at overlapping sites: the complexity of protein-protein interactions for channel regulation.
    Vervliet T; Parys JB; Bultynck G
    Biochem Soc Trans; 2015 Jun; 43(3):396-404. PubMed ID: 26009182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bcl-xL acts as an inhibitor of IP
    Rosa N; Ivanova H; Wagner LE; Kale J; La Rovere R; Welkenhuyzen K; Louros N; Karamanou S; Shabardina V; Lemmens I; Vandermarliere E; Hamada K; Ando H; Rousseau F; Schymkowitz J; Tavernier J; Mikoshiba K; Economou A; Andrews DW; Parys JB; Yule DI; Bultynck G
    Cell Death Differ; 2022 Apr; 29(4):788-805. PubMed ID: 34750538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Bcl-2 protein family member Bok binds to the coupling domain of inositol 1,4,5-trisphosphate receptors and protects them from proteolytic cleavage.
    Schulman JJ; Wright FA; Kaufmann T; Wojcikiewicz RJH
    J Biol Chem; 2013 Aug; 288(35):25340-25349. PubMed ID: 23884412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Creating a New Cancer Therapeutic Agent by Targeting the Interaction between Bcl-2 and IP
    Distelhorst CW; Bootman MD
    Cold Spring Harb Perspect Biol; 2019 Sep; 11(9):. PubMed ID: 31110129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.
    Lavik AR; Zhong F; Chang MJ; Greenberg E; Choudhary Y; Smith MR; McColl KS; Pink J; Reu FJ; Matsuyama S; Distelhorst CW
    Oncotarget; 2015 Sep; 6(29):27388-402. PubMed ID: 26317541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Insights in the IP
    Parys JB; Vervliet T
    Adv Exp Med Biol; 2020; 1131():243-270. PubMed ID: 31646513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profiling of the Bcl-2/Bcl-X(L)-binding sites on type 1 IP(3) receptor.
    Monaco G; Beckers M; Ivanova H; Missiaen L; Parys JB; De Smedt H; Bultynck G
    Biochem Biophys Res Commun; 2012 Nov; 428(1):31-5. PubMed ID: 23058917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HA14-1 potentiates apoptosis in B-cell cancer cells sensitive to a peptide disrupting IP 3 receptor / Bcl-2 complexes.
    Akl H; La Rovere RM; Janssens A; Vandenberghe P; Parys JB; Bultynck G
    Int J Dev Biol; 2015; 59(7-9):391-8. PubMed ID: 26260683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.